Skin Cancer/Melanoma Breakout: Learning from a decade of success

Immunotherapy has forever changed the way melanoma is treated. Checkpoint inhibitors, beginning with the landmark 2011 FDA approval of ipilimumab (Yervoy®), are responsible for the increasing survival rates for patients with metastatic melanoma. Join Dr. Jeffrey Weber, professor at Perlmutter Cancer Center at NYU Langone, in a Q&A discussion about how immunotherapy is increasing the survival rate for patients with metastatic melanoma and how doctors are bringing the benefits of immunotherapy to more melanoma patients.

Видео Skin Cancer/Melanoma Breakout: Learning from a decade of success канала Cancer Research Institute